CUMBERLAND PHARMACEUTICALS INC (CPIX): debt financing — Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027

CUMBERLAND PHARMACEUTICALS INC

Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).
Maturity extended to October 1, 2027; interest rate is Benchmark Term SOFR + 2.75%.
New financial covenant: Minimum Fixed Charge Coverage Ratio of 1.75x, replacing Maximum Funded Debt Ratio.
Borrowing Base Requirements made permanent; company paid $15,000 amendment fee.
Collateral remains substantially all assets; credit line with Pinnacle Bank.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $15 million with Pinnacle Bank at Benchmark Term SOFR plus 2.75% maturing October 1, 2027.

Instrument: revolving credit
Principal: up to $15 million
Counterparty: Pinnacle Bank
Rate: Benchmark Term SOFR plus 2.75%
Maturity: October 1, 2027
Event: incurrence

Exact text from the filing

The Amendment provides for a principal available for borrowing of up to $15 million.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CUMBERLAND PHARMACEUTICALS INC amended First Amendment to Amended and Restated Revolving Credit Note and Second Amendment to Amended and Restated Revolving Credit Loan Agreement with Pinnacle Bank valued at $15 million (effective 2025-11-18).

Action: amendment
Agreement: credit facility
Counterparty: Pinnacle Bank
Value: $15 million
Effective: 2025-11-18

Exact text from the filing

On November 18, 2025, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”) and Pinnacle Bank ("Pinnacle") fully executed the First Amendment to Amended and Restated Revolving Credit Note and Second Amendment to Amended and Restated Revolving Credit Loan Agreement

View on SEC.gov

Browse all debt financings →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001087294-25-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.